Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
Psychedelics
Mind Cure Receives Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
Compass Pathways has closed its IPO financing, raising $146.6 million via the sale of 8,625,000 American Depository Shares.
Psychedelics Stock Warrants Offer Interesting Leverage Play
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
PharmaDrug Inc. Closes Transaction to Acquire First Smart Shop in the Netherlands, Initiates Major Push to Acquire Best of Breed High Traffic Locations
PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.
MindMed Catches Fire, Seeks To Up-List On NASDAQ
MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
IPOs Drive Big Gains In Psychedelic Stocks
IPO fever is sweeping through the psychedelics space.
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
MindMed Inc has applied to up-list on the NASDAQ.
Numinus Announces Listing of Warrants
Numinus warrants have an exercise price of CAD$0.35 and are valid until September 10, 2022.
Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs
Revive's corporate update centers on psilocybin research on a new delivery system and addiction treatment.
Mind Cure Targets Multi-Billion Dollar Sweet-Spot in Life Sciences
The road to psychedelic drug success leads through functional mushrooms.
Why Canada Is The Natural Launch-Pad For The Psychedelic Drug Industry
Canada stands out as the premier destination for psychedelic drug companies.
An Investing Roadmap For The Mental Health Crisis
A $225 billion treatment market is badly in need of new therapies. Here is the roadmap for investors to capitalize on this opportunity.
COMPASS Pathways announces pricing of upsized initial public offering
Compass Pathways has upsized its IPO financing to $127.5 million, at an offering price of $17.00 per American Depositiry Share (ADS).